Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study.
Oligodendrogliopathy in Multiple Sclerosis: Low Glycolytic Metabolic Rate Promotes Oligodendrocyte Survival.
Ncx3 gene ablation impairs oligodendrocyte precursor response and increases susceptibility to experimental autoimmune encephalomyelitis.
Susceptibility tensor imaging (STI) of the brain.
Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29 000 subjects.
The effects of diet on the severity of central nervous system disease: One part of lab-to-lab variability.
The role of global and regional gray matter volume decrease in multiple sclerosis.
Brain-gut axis and pentadecapeptide BPC 157. Theoretical and practical implications.
Akt Regulates Axon Wrapping and Myelin Sheath Thickness in the PNS.
Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients.
Myelin injury induces axonal transport impairment but not AD-like pathology in the hippocampus of cuprizone-fed mice.
The possible effects of the solar and geomagnetic activity on multiple sclerosis.
Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.
Multi-parametric quantitative MRI of normal appearing white matter in multiple sclerosis, and the effect of disease activity on T2.
Mutually enhancing anti-inflammatory activities of dimethyl fumarate and NF-κB inhibitors - Implications for dose-sparing combination therapies.
Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use.
A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis.
The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.
Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
Moving Targets for Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.
Magnetic resonance imaging of myelin using ultrashort Echo time (UTE) pulse sequences: Phantom, specimen, volunteer and multiple sclerosis patient studies.
B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells.
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis.
Optimal combination of FLAIR and T2-weighted MRI for improved lesion contrast in multiple sclerosis.
Teriflunomide attenuates immunopathological changes in the dark agouti rat model of experimental autoimmune encephalomyelitis.

Pages